Cadila Healthcare is currently trading at Rs 740.00, up by 1.10 points or 0.15% from its previous closing of Rs 738.90 on the BSE.
The scrip opened at Rs 744.75 and has touched a high and low of Rs 746.10 and Rs 733.00 respectively. So far 3260 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 695.00 on 16-Apr-2012.
Last one week high and low of the scrip stood at Rs 767.00 and Rs 735.30 respectively. The current market cap of the company is Rs 15087.92 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.
Cadila Healthcare, part of the ZydusCadila group, is reportedly planning to launch an indigenously developed molecule for diabetes dyslipidemia, which is expected to be called Saroglitizar. The company has been working on a new molecule since 2004. At present, the company has several molecules under its research pipeline which it hopes to bring to the market.
Recently, Zydus Cadila received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sale in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment, was $15.5 million.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1815.00 |
Dr. Reddys Lab | 1351.50 |
Cipla | 1476.15 |
Lupin | 2172.00 |
Zydus Lifesciences | 974.20 |
View more.. |